ABAndrew Blease

Andrew Blease

*This is an algorithmically generated author record based on publicly available information.

Andrew Blease has a total of 172 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution

    by Hilke Ehlich, Andrew Blease, Reva Biju, Montse Gustems, Fei Song, Sabine Fessele, Marzia Massimi, Konstantinos Bozonelos, Vasileios Ntafis, Anniina E. Hiltunen, et al.

    The future of biomedical research. In this capacity, EMMA plays a vital role in addressing major challenges in biomedical research, such as resource quality, enhancing reproducibility, and promoting ethical animal use. By cryopreserving genetically modified strains, repositories, such as EMMA, reduce the need for continuous live breeding, aligning with the 3Rs principle-Replace, Reduce, Refine-mandated by EU Directive 2010/63/EU (Russell and Burch 1992; Lloyd et al. 2015; Allen et al. 2023) yet not compromising the reproducibility of research


  • Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy

    by Ying-Jie Wang, Kamayani Singh, Adam B. Lokman, Siwei Deng, Balaraju Sunitha, Jose Coelho Lima Jr., Julia Beglov, Matthew Kelly, Andrew Blease, Jacky C. K. Fung, et al.

    Hypertrophic cardiomyopathy (HCM) is a common, serious, genetic heart muscle disorder. Although the biophysical mechanisms by which gene variants in sarcomeric proteins disrupt cardiomyocyte function are largely understood, the cellular and molecular pathways leading to the complex, variable, and adverse remodeling of the non-myocyte compartment are unexplained. Here, we report that postmortem and explanted human HCM hearts exhibited chronic focal leukocyte infiltration and prominent activation of immune cells. Gene set enrichment analysis (GSEA) revealed that active immune responses were present in the mid- and late-stage HCM human hearts and in mouse hearts from several HCM mouse models. The alpha cardiac actin 1-E99K ( Actc1 E99K ) HCM mouse model was selected for the study because it closely recapitulates the features of progressive remodeling and fibrosis seen in advanced disease in patients. Genetic depletion of lymphocytes in recombination activating gene 1–knockout ( Rag-1 KO ) mice led to marked exacerbation of adverse cardiac remodeling in the Actc1 E99K mice. Detailed characterization of cardiac regulatory T cells (T reg cells) demonstrated a time-dependent increase in Actc1 E99K hearts with altered immunosuppressive profiles. Adoptive transfer of splenic T reg cells reduced cardiac fibrosis and improved systolic dysfunction in Actc1 E99K mice with or without lymphocytes. In addition, low-dose interleukin-2 (IL-2)/anti–IL-2 complex (IL-2/c), which specifically induced T reg cell expansion in vivo, ameliorated cardiac fibrosis and reduced macrophage infiltration and activation in Actc1 E99K mice. These data contribute to our understanding of HCM and support the use of T reg cells as a clinically testable therapeutic strategy for cardiac fibrosis in the HCM heart.


  • Open Access

    Tissue-specific differences in the assembly of mitochondrial Complex I are revealed by a novel ENU mutation in ECSIT

    by Thomas Nicol, Sara Falcone, Andrew Blease, Pratik Vikhe, Gabriele Civiletto, Saleh Salman Omairi, Carlo Viscomi, Ketan Patel, Paul K Potter

    Aims: Mitochondrial Complex I assembly (MCIA) is a multi-step process that necessitates the involvement of a variety of assembly factors and chaperones to ensure that the final active enzyme is correctly assembled. The role of the assembly factor evolutionarily conserved signalling intermediate in the toll (ECSIT) pathway was studied across various murine tissues to determine its role in this process and how this varied between tissues of varying energetic demands. We hypothesized that many of the known functions of ECSIT were unhindered by the introduction of an ENU-induced mutation, while its role in Complex I assembly was affected on a tissue-specific basis. Methods and results: Here, we describe a mutation in the MCIA factor ECSIT that reveals tissue-specific requirements for ECSIT in Complex I assembly. MCIA is a multi-step process dependent on assembly factors that organize and arrange the individual subunits, allowing for their incorporation into the complete enzyme complex. We have identified an ENU-induced mutation in ECSIT (N209I) that exhibits a profound effect on Complex I component expression and assembly in heart tissue, resulting in hypertrophic cardiomyopathy in the absence of other phenotypes. The dysfunction of Complex I appears to be cardiac specific, leading to a loss of mitochondrial output as measured by Seahorse extracellular flux and various biochemical assays in heart tissue, while mitochondria from other tissues were unaffected. Conclusions: These data suggest that the mechanisms underlying Complex I assembly and activity may have tissue-specific elements tailored to the specific demands of cells and tissues. Our data suggest that tissues with high-energy demands, such as the heart, may utilize assembly factors in different ways to low-energy tissues in order to improve mitochondrial output. These data have implications for the diagnosis and treatment of various disorders of mitochondrial function as well as cardiac hypertrophy with no identifiable underlying genetic cause.


  • Open Access

    Comparing the effects of chemical Ca2+ dyes and R-GECO on contractility and Ca2+ transients in adult and human iPSC cardiomyocytes

    by Paul Robinson, Alexander J. Sparrow, Yiangos Psaras, Violetta Steeples, Jillian N. Simon, Connor N. Broyles, Yu-Fen Chang, Frances A. Brook, Ying-Jie Wang, Andrew Blease, et al.


  • Open Access

    Chronically elevated branched chain amino acid levels are pro-arrhythmic

    by Vincent Portero, Thomas Nicol, Svitlana Podliesna, Gerard A Marchal, Antonius Baartscheer, Simona Casini, Rafik Tadros, Jorien L Treur, Michael W T Tanck, I Jane Cox, et al.

    Cardiac arrhythmias comprise a major health and economic burden and are associated with significant morbidity and mortality, including cardiac failure, stroke, and sudden cardiac death (SCD). Development of efficient preventive and therapeutic strategies is hampered by incomplete knowledge of disease mechanisms and pathways. Our aim is to identify novel mechanisms underlying cardiac arrhythmia and SCD using an unbiased approach. We employed a phenotype-driven N-ethyl-N-nitrosourea mutagenesis screen and identified a mouse line with a high incidence of sudden death at young age (6–9 weeks) in the absence of prior symptoms. Affected mice were found to be homozygous for the nonsense mutation Bcat2p.Q300*/p.Q300* in the Bcat2 gene encoding branched chain amino acid transaminase 2. At the age of 4–5 weeks, Bcat2p.Q300*/p.Q300* mice displayed drastic increase of plasma levels of branch chain amino acids (BCAAs—leucine, isoleucine, valine) due to the incomplete catabolism of BCAAs, in addition to inducible arrhythmias ex vivo as well as cardiac conduction and repolarization disturbances. In line with these findings, plasma BCAA levels were positively correlated to electrocardiogram indices of conduction and repolarization in the German community-based KORA F4 Study. Isolated cardiomyocytes from Bcat2p.Q300*/p.Q300* mice revealed action potential (AP) prolongation, pro-arrhythmic events (early and late afterdepolarizations, triggered APs), and dysregulated calcium homeostasis. Incubation of human pluripotent stem cell-derived cardiomyocytes with elevated concentration of BCAAs induced similar calcium dysregulation and pro-arrhythmic events which were prevented by rapamycin, demonstrating the crucial involvement of mTOR pathway activation. Our findings identify for the first time a causative link between elevated BCAAs and arrhythmia, which has implications for arrhythmogenesis in conditions associated with BCAA metabolism dysregulation such as diabetes, metabolic syndrome, and heart failure.


  • Open Access

    Modification of an aggressive model of Alport Syndrome reveals early differences in disease pathogenesis due to genetic background

    by Sara Falcone, Laura Wisby, Thomas Nicol, Andrew Blease, Becky Starbuck, Andrew Parker, Jeremy Sanderson, Steve D. M. Brown, Cheryl L. Scudamore, Charles D. Pusey, et al.

    The link between mutations in collagen genes and the development of Alport Syndrome has been clearly established and a number of animal models, including knock-out mouse lines, have been developed that mirror disease observed in patients. However, it is clear from both patients and animal models that the progression of disease can vary greatly and can be modified genetically. We have identified a point mutation in Col4a4 in mice where disease is modified by strain background, providing further evidence of the genetic modification of disease symptoms. Our results indicate that C57BL/6J is a protective background and postpones end stage renal failure from 7 weeks, as seen on a C3H background, to several months. We have identified early differences in disease progression, including expression of podocyte-specific genes and podocyte morphology. In C57BL/6J mice podocyte effacement is delayed, prolonging normal renal function. The slower disease progression has allowed us to begin dissecting the pathogenesis of murine Alport Syndrome in detail. We find that there is evidence of differential gene expression during disease on the two genetic backgrounds, and that disease diverges by 4 weeks of age. We also show that an inflammatory response with increasing MCP-1 and KIM-1 levels precedes loss of renal function.


  • Open Access

    Studying Osteoarthritis Pathogenesis in Mice

    by Andrew Blease, Patricia Das Neves Borges, Marcia Curtinha, Behzad Javaheri, Isabell S. von Loga, Ida Parisi, Jadwiga Zarebska, Andrew Pitsillides, Tonia L. Vincent, Paul K. Potter

    With the increasing availability and complexity of mouse models of disease, either spontaneous or induced, there is a concomitant increase in their use in the analysis of pathogenesis. Among such diseases is osteoarthritis, a debilitating disease with few treatment options. While advances in our understanding of the pathogenesis of osteoarthritis has advanced through clinical investigations and genome‐wide association studies, there is still a large gap in our knowledge, hindering advances in therapy. Patient samples are available ex vivo, but these are generally in the very late stages of disease. However, with mice, we are able to induce disease at a defined time and track the progression in vivo and ex vivo, from inception to end stage, to delineate the processes involved in disease development. © 2018 by John Wiley & Sons, Inc.


  • Open Access

    Generation and Identification of Mutations Resulting in Chronic and Age‐Related Phenotypes in Mice

    by Andrew Blease, Thomas Nicol, Sara Falcone, Becky Starbuck, Simon Greenaway, Marie Hutchinson, Paul K. Potter

    Aging is inevitable, and our society must deal with the consequences: namely, an increased incidence of disease and ill health. Many mouse models of disease are acute or early onset or are induced in young mice, despite the fact that aging is a significant risk factor for a range of significant diseases. To improve modeling of such diseases, we should incorporate aging into our models. Many systems are affected by aging, with a decline in mitochondrial function, an increase in senescence, a loss of resilience, telomere shortening, and a decline in immune function being key factors in the increased susceptibility to disease that is associated with aging. To develop novel models of age‐related disease, we undertook a phenotype‐driven screen of a pipeline of mutagenized mice. Here, we describe some of the underlying protocols and outline important aspects to consider when studying aged mice. © 2018 by John Wiley & Sons, Inc.


  • Open Access

    Novel gene function revealed by mouse mutagenesis screens for models of age-related disease

    by Paul K Potter, Michael R Bowl, Prashanthini Jeyarajan, Laura Wisby, Andrew Blease, Michelle E Goldsworthy, Michelle M Simon, Simon Greenaway, Vincent Michel, Alun Barnard, et al.

    Determining the genetic bases of age-related disease remains a major challenge requiring a spectrum of approaches from human and clinical genetics to the utilization of model organism studies. Here we report a large-scale genetic screen in mice employing a phenotype-driven discovery platform to identify mutations resulting in age-related disease, both late-onset and progressive. We have utilizedN-ethyl-N-nitrosourea mutagenesis to generate pedigrees of mutagenized mice that were subject to recurrent screens for mutant phenotypes as the mice aged. In total, we identify 105 distinct mutant lines from 157 pedigrees analysed, out of which 27 are late-onset phenotypes across a range of physiological systems. Using whole-genome sequencing we uncover the underlying genes for 44 of these mutant phenotypes, including 12 late-onset phenotypes. These genes reveal a number of novel pathways involved with age-related disease. We illustrate our findings by the recovery and characterization of a novel mouse model of age-related hearing loss.